Pulmonary, Allergy and Critical Care Division, University of Pennsylvania Medical Center, 835 West Gates Building, 3600 Spruce Street, Philadelphia, PA 19104, USA.
Curr Infect Dis Rep. 2009 May;11(3):216-22. doi: 10.1007/s11908-009-0032-4.
Although advances in surgical technique, immunosuppressive regimens, and medical management have led to improved survival and quality of life after solid organ transplantation, infection continues to represent a major cause of morbidity and mortality in transplant recipients. Immunosuppressive therapy after transplantation compromises cell-mediated immunity in particular, leaving the patient at risk for opportunistic as well as routine community-acquired infections. Mycobacterial infection is a rare but important complication of solid organ transplantation, presenting significant risk to the patient and challenges in terms of treatment. The available literature consists predominantly of case reports and institutional experiences. This article examines both Mycobacterium tuberculosis and nontuberculous mycobacterial infection in the transplant setting.
尽管手术技术、免疫抑制方案和医疗管理的进步提高了实体器官移植后的生存率和生活质量,但感染仍然是移植受者发病率和死亡率的主要原因。移植后免疫抑制治疗特别损害细胞介导的免疫,使患者面临机会性和常规社区获得性感染的风险。分枝杆菌感染是实体器官移植的一种罕见但重要的并发症,给患者带来重大风险,并在治疗方面带来挑战。现有文献主要由病例报告和机构经验组成。本文研究了移植环境中的结核分枝杆菌和非结核分枝杆菌感染。